Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | WHR1 | P49842 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097139 | 0.93 | CYP1A1 (0.33) | ATMCYP1A1CYP1A2CYP1B1MEN1 | |
| SCHEMBL22097033 | 0.89 | ATM (0.35) | ATMKDM4EL3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL22097034 | 0.88 | ATM (0.38) | ATMKDM4EL3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL22097156 | 0.87 | MEN1 (0.45) | ATMKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL22097035 | 0.87 | PTGES (0.36) | ATMKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL22096952 | 0.85 | MAPT (0.33) | KDM4ECYP1A1CYP1A2CYP1B1MEN1 | |
| SCHEMBL22097074 | 0.85 | L3MBTL1 (0.42) | ATMKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL22097075 | 0.85 | L3MBTL1 (0.42) | ATMKDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL18026408 | 0.84 | ATM (0.39) | ATMKDM4EL3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL17829209 | 0.84 | L3MBTL1 (0.41) | ATMKDM4EL3MBTL1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236075-B2 | Organic compound and organic electroluminescence device using the same | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2022-02-01 | — | — | US | disclosed |
| US-20200190065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236075-B2 | Organic compound and organic electroluminescence device using the same | ICMT, OR10J3, PIEZO1 | ATM 3884/4885KDM4E 1846/4885L3MBTL1 179/4885 |
| US-20200190065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | ICMT, OR10J3, PIEZO1 | ATM 3884/4885KDM4E 1846/4885L3MBTL1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.